Mackenzie Financial Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Mackenzie Financial raised its stake in Regeneron by 26.8% to 128,623 shares (about $72.3M), and overall institutional ownership of the stock is high at 83.31%.
• Regeneron beat quarterly estimates (EPS $11.44 vs. $10.74 expected; revenue $3.88B vs. $3.76B) and raised its quarterly dividend to $0.94 ($3.76 annualized); the company has a market cap of $81.9B and a P/E of ~18.6.
• Analyst sentiment is mixed: the consensus is a "Moderate Buy" with an average price target of $802.27, but some analysts warn the stock is now "fairly valued" and may have limited near‑term upside while others (e.g., Barclays) remain more bullish with a higher target.

Mackenzie Financial Corp boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 26.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,623 shares of the biopharmaceutical company's stock after purchasing an additional 27,205 shares during the period. Mackenzie Financial Corp owned approximately 0.12% of Regeneron Pharmaceuticals worth $72,321,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Franklin Resources Inc. increased its position in Regeneron Pharmaceuticals by 6.0% during the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company's stock valued at $1,379,329,000 after acquiring an additional 139,647 shares during the last quarter. Magnetar Financial LLC boosted its position in Regeneron Pharmaceuticals by 178.1% in the third quarter. Magnetar Financial LLC now owns 1,307 shares of the biopharmaceutical company's stock worth $735,000 after purchasing an additional 837 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Regeneron Pharmaceuticals by 78.0% in the third quarter. Quadrant Capital Group LLC now owns 3,568 shares of the biopharmaceutical company's stock worth $2,006,000 after purchasing an additional 1,564 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Capital Research Global Investors now owns 105,749 shares of the biopharmaceutical company's stock valued at $59,455,000 after purchasing an additional 3,635 shares during the period. Finally, Capital World Investors increased its position in shares of Regeneron Pharmaceuticals by 1.6% during the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company's stock valued at $1,123,609,000 after purchasing an additional 32,348 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EU regulatory progress for Dupixent: reporting notes that the CHMP gave a positive opinion supporting Dupixent for children aged 2–11 with chronic spontaneous urticaria in the EU — a label expansion that could help sustain Dupixent revenue momentum in Europe. Sanofi’s EU Drug Wins Contrast With Weak Share Momentum And Valuation Gap
• Positive Sentiment: Corporate goodwill and brand visibility from science outreach: Regeneron’s sponsorship of the Regeneron Science Talent Search (awarding more than $1.8M) is positive for reputation and stakeholder relations — a modest supportive factor for investor sentiment. Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists
• Neutral Sentiment: Management presentations (Leerink, Barclays): Regeneron posted transcripts from recent conferences (Leerink, Barclays). These maintenances of visibility and messaging help keep investors informed about pipeline priorities (Dupixent, Libtayo, other assets) but did not introduce major new catalysts. Regeneron Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Barclays conference transcript provides additional management commentary but no headline surprises; useful for modeling guidance and pipeline timing. Regeneron Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Sector roundup context: broader health‑care coverage (eczema treatments, Roche pipeline) underscores competitive dynamics in dermatology and immunology — contextually relevant to Dupixent but not an immediate Regeneron‑specific catalyst. Health Care Roundup: Market Talk
• Negative Sentiment: Analyst view warns of limited near‑term upside: a recent analysis argues REGN is “fairly valued” after a strong run and expects near‑term sideways trading because there are few immediate new revenue drivers; it also notes declining Eylea/Eylea HD sales that will need to be offset by Dupixent and future pipeline contributions. That view can cap short‑term upside despite long‑term confidence in Dupixent. Regeneron: Fairly Valued Now After A Stellar Upswing

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $774.66 on Thursday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The stock has a market cap of $81.90 billion, a price-to-earnings ratio of 18.64, a PEG ratio of 2.07 and a beta of 0.41. The company's 50 day moving average is $770.85 and its two-hundred day moving average is $692.59.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts' consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company's revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business posted $12.07 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's payout ratio is currently 9.05%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a "buy" rating on the stock in a research note on Monday, February 2nd. Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an "equal weight" rating in a report on Monday, February 2nd. Barclays began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, March 6th. They set an "overweight" rating and a $923.00 price target on the stock. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, HSBC started coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a "buy" rating and a $255.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.